布地格福用于慢性阻塞性肺疾病稳定期临床评价

Clinical Evaluation of Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol in Stable Phase of Chronic Obstructive Pulmonary Disease

目的探讨布地格福在慢性阻塞性肺疾病(简称慢阻肺)稳定期中的应用价值。方法选取医院2021年1月至2023年1月收治的慢阻肺稳定期患者45例,根据治疗方法的不同分为对照组(23例)和观察组(22例)。对照组患者予布地奈德福莫特罗治疗,观察组患者予布地格福治疗,两组患者均治疗10 d。结果观察组总有效率为90.91%,显著高于对照组的60.87%(P<0.05)。治疗后,观察组患者的血氧分压(PaO_(2))显著高于对照组,血二氧化碳分压(PaCO_(2))、呼吸频率(RR)、心率(HR)均显著低于对照组(P<0.05);观察组患者的肺功能指标用力肺活量(FVC)、第1秒用力呼气容积(FEV_(1))、FEV_(1)/FVC均显著高于对照组(P<0.05);观察组患者的圣乔治呼吸问卷(SGRQ)疾病影响、症状与活动能力评分均显著低于对照组(P<0.05)。结论布地格福治疗慢阻肺稳定期的临床疗效良好,可改善患者的肺功能和血气分析指标,稳定其HR和RR,提高生活质量。

Objective To investigate the application value of Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol in the stable phase of chronic obstructive pulmonary disease(COPD).Methods Forty five stable patients with chronic obstructive pulmonary disease(COPD)admitted to the hospital from January 2021 to January 2023 were selected and divided into the control group(23 cases)and the observation group(22 cases)by different treatment methods.The control group was treated with Budesonide and Formoterol Fumarate,while the observation group was treated with Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol.Both groups were treated for 10 d.Results The total effective rate in the observation group was 90.91%,which was significantly higher than 60.87%in the control group(P<0.05).After treatment,the partial pressure of blood oxygen(PaO_(2))in the observation group was significantly higher than that in the control group,while the partial pressure of blood carbon dioxide(PaCO_(2)),respiratory rate(RR),and heart rate(HR)in the observation group were significantly lower than those in the control group(P<0.05).The lung function indicators including forced vital capacity(FVC),forced expiratory volume at 1 second(FEV_(1)),and FEV_(1)/FVC in the observation group were significantly higher than those in the control group(P<0.05).The Saint George's Respiratory Questionnaire(SGRQ)disease impact,symptoms,and activity scores in the observation group were significantly lower than those in the control group(P<0.05).Conclusion Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol is effective in the treatment of stable phase of chronic obstructive pulmonary disease,which can improve the patient's lung function and blood gas analysis indicators,stabilize their HR and RR,and improve their quality of life.